Ruben Geevarghese, MD, MSc
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Liver cancer and conditions
- Bile duct cancer (cholangiocarcinoma)
My Specialties
- Interventional radiology
- Radioembolization
- Embolization
Get to Know Me
I am an interventional radiologist, which is a physician who specializes in using image-guided, minimally invasive techniques to treat and diagnose various conditions including cancer. I am part of the hepatobiliary disease management team at Memorial Sloan Kettering Cancer Center (MSK), where I collaborate closely with surgeons, gastrointestinal medical oncologists and other specialists to ensure each patient receives coordinated and personalized care. Using CT, ultrasound, fluoroscopy (X-ray imaging), or MRI, I perform procedures through tiny incisions—often no larger than a needle—which can help patients avoid more invasive surgery, recover faster, and experience fewer complications.
I often do procedures that help treat or diagnose cancer, with a focus on treating liver and bile duct cancers. These include:
- Using imaging tools with a small probe placed through the skin to guide the destruction of tumors (called image-guided ablation)
- Treating tumors via their blood flow to shrink or kill them (called embolization, including a special kind called Y-90)
- Taking samples of tissue to check for cancer (biopsies)
- Placing ports to make it easier for patients to receive treatments like chemotherapy
Each of these methods is designed to either get rid of cancer, shrink it, or help figure out what kind of cancer it is.
When patients first meet me, they’re often anxious about the unknown—what a procedure involves or how long their recovery will take. I take the time to walk each patient through what to expect, discuss their imaging with them, and answer questions clearly and with care. I understand that even “routine” procedures are never routine for the person experiencing them.
I was drawn to this field because it combines hands-on, minimally invasive treatment options and evolving techniques that can make a profound impact to people’s lives. It’s a privilege to offer treatments that are less invasive yet incredibly powerful—and to do so at MSK, where every member of the care team shares a deep commitment to excellence, collaboration and compassion.
I'm an interventional (IN-ter-VEN-shun-al) radiologist. This is a doctor with special training in using image-guided procedures to diagnose and treat disease.
- Interventional Radiologist
Conditions I Treat
- Liver cancer and conditions
- Bile duct cancer (cholangiocarcinoma)
My Specialties
- Interventional radiology
- Radioembolization
- Embolization
- Ablation
- Image-guided biopsy
- Port
Education
- Medicine, King's College London
- Clinical Neuroscience, MSc, King's College London
Residencies
- Interventional Radiology and Diagnostic Radiology, West Midlands, United Kingdom
Fellowships
- Interventional Oncology, Memorial Sloan Kettering Cancer Center
- Interventional Radiology, McGill University
- Interventional Radiology, McMaster University
Awards and Honors
- Top Reviewer Award, Journal of Vascular and Interventional Radiology (2025)
- Best Educational Exhibit Award, Society of Interventional Radiology (2025)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
State Government
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Geevarghese R, Solomon SB, Alexander ES, Marinelli B, Chaterjee S, Jain P, Cadley J, Hollingsworth A, Chatterjee A, Ziv E. Utility of a large language model for extraction of clinical findings from healthcare data following lung ablation: A feasibility study. Journal of Vascular and Interventional Radiology. 2025.
Geevarghese R, Kunin H, Petre EN, Deng R, Jain S, Sotirchos VS, Zhao K, Sofocleous CT, Solomon SB, Ziv E, Alexander E. Microwave Ablation of Refractory Oligometastatic Non-Small Cell Lung Cancer in the Liver. Journal of Vascular and Interventional Radiology. 2024.
Son S, Velayati S, Zhao K, Marinelli B, Geevarghese R, Sotirchos VS, Covey A, Harding JJ, D’Angelica MI, Jaranagin WR, Wei A, Yarmohammadi H. Outcomes of Transarterial Hepatic Embolization versus Yttrium-90 Radioembolization for Treatment of Patients with Hepatocellular Carcinoma > 7 cm. Journal of Vascular and Interventional Radiology. 2025.
Geevarghese R, Sigel C, Cadley J, Chaterjee S, Jain P, Cadley J, Hollingsworth A, Chatterjee A, Swinburne N, Bilal KH, Marinelli B. Extraction and classification of structured data from unstructured hepato-biliary pathology reports using large language models: A feasibility study compared to rules-based natural language processing. Journal of Clinical Pathology. 2024.
Geevarghese R, Harding J, Parsons N, Hutchinson C, Parsons C. The relationship of embolic particle size to patient outcomes in Prostate Artery Embolisation for Benign Prostatic Hyperplasia: A systematic review and meta-regression. Clinical Radiology. 2020.
Visit PubMed for a full listing of Dr. Geevarghese’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Ruben Geevarghese discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].